• For Individuals
  • For Institutions
  • Download
  • Help

  • About

longbridgelongbridge
longbridgelongbridge
Why Longbridge?
Investment Products
Trading Tools
Trading Platform
Developers
Market Data Services
Analysis Tools
News Services
Dolphin Research
Pricing
Markets
Global Markets
Stock Screener
Information
Research
News
Live
Community
Academy
Promotions
EN
English
简体中文
繁體中文
繁體中文（廣東話）Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
Posts
News
Financials

Event Tracking

Nov7
Hengrui Medicine's Subsidiary Obtains Clinical Trial Approval for SHR-4610 Injection
09:43
Nov6
Wellington Management Increases Holdings in Hengrui Medicine by 855,600 Shares
13:18
Nov5
Hengrui Medicine Announces Clinical Trial Results of GLP-1/GIP Dual Receptor Agonist HRS9531 and Submits New Drug Application
00:06
Nov3
Hengrui Medicine Repurchased 100,000 A-shares for 6.3223 Million Yuan
08:48
Hengrui Medicine Subsidiary's HRS-5965 Capsule Proposed for Priority Review List
08:43
Hengrui Medicine Repurchasing Shares for Employee Stock Ownership Plan
08:41

Schedules & Filings

Schedules
Filings
Oct27
Earning Release(CST)

FY2025 Q3 Earning Release (HKD) Revenue 8.119 B, Net Income 1.422 B, EPS 0.2131

Aug20
Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 9.364 B, Net Income 2.82 B, EPS 0.4359

May23
IPO(CST)

Listing Price HKD 44.05

View More

Stock List

Top Gainers
Top Decliners
Main Board
Symbol
Price
%Chg
Change
00704
0.230
+139.58%
+0.134
00464
1.920
+71.43%
+0.800
00036
0.233
+61.81%
+0.089
03822
1.120
+43.59%
+0.340
03708
0.056
+40.00%
+0.016
01792
0.053
+35.90%
+0.014
00095
0.300
+29.31%
+0.068
08106
0.360
+26.32%
+0.075
02358
0.015
+25.00%
+0.003
01150
0.166
+24.81%
+0.033
View More
Terms & Conditions
  • Terms of Service
  • Privacy Policy